Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScanTM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)

/in

NephroScan is now US FDA approved for the preparation of Tc-99m DMSA NephroScan aids in the detection of kidney cortical defects in adult and pediatric patients, including term neonates GE Healthcare to commence distribution in the US Manufactured by ROTOP Pharmaka in Germany LONDON, UK, 23 February 2022 – Theragnostics announces that NephroScan, its radiodiagnostic imaging drug used […]

Read more

Study indicates that AMSilk engineered silk implant coatings can prevent infection

/in

Repellence properties of silk coatings reduced microbial adherence up to 99.7% in comparison to uncoated silicone surfaces Spider silk coatings have the potential to prevent inflammation and to reduce post-operative complications of implants Previous studies suggest safe & effective use in humans Munich, Germany, 22 February 2022 – AMSilk GmbH (“AMSilk”), a world leader in supplying […]

Read more

TargED raises €39 million in a series A investment round

/in

TargED is extremely pleased and proud to have raised €39 million in a Series A investment round! Together with an international investor syndicate  we’ll pursue our common goal: to bring Microlyse into clinical development! Read press release

Read more

ISA Pharmaceuticals to Attend Multiple In Person Conferences in Early 2022

/in

Oegstgeest, the Netherlands, February 17, 2022 – ISA Pharmaceuticals will be attending the following in person scientific and business conferences from February through to April 2022 (subject to travel restrictions), in addition to virtual conferences. Read more…

Read more

Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting

/in

Data demonstrates first-in-class potential as a regenerative treatment of Stress Urinary Incontinence Treatment results in muscle regeneration with restored functionality in pre-clinical models Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its  Chief Scientific Officer, Friedrich Metzger will be presenting data on the Company’s mRNA […]

Read more
© Optimum Strategic Communications.